α-Tocopherols modify the membrane dipole potential leading to modulation of ligand binding by P-glycoprotein by Davis, Sterenn et al.
1 
 
α-Tocopherols Modify the Membrane Dipole Potential Leading to Modulation of Ligand 
Binding by P-glycoprotein  
 
Sterenn Davis1*, Benjamin M. Davis2#, Joanna L. Richens2, Kelly-Ann Vere2, Peter G. Petrov1, 
C. Peter Winlove1, Paul O’Shea2ǂ 
 
1 Biomedical Physics Group, School of Physics, University of Exeter, Exeter, United Kingdom 
2 Cell Biophysics Group, School of Life Sciences, University of Nottingham, Nottingham, NG7 
2RD United Kingdom 
 
 
*Current address: Immunocore Limited. 91 Park Drive, Milton Park, Abingdon OX14 4RY 
Oxon. 
#Current address: Institute of Ophthalmology, University College London, 11-43 Bath Street, 
London EC1V 9EL 
 
ǂCorresponding Author: Professor Paul O’Shea, Email: paul.oshea@nottingham.ac.uk, Tel: 
+44(0)115 951 3209, Fax +44(0)115 846 6580 
 
Running title: α-Tocopherol modulation of P-glycoprotein activity 
 
Abbreviations: Di-8-ANEPPS ((1-(3-sulfonatopropyl)-4-[β[2-(di-n-octylamino)-6-
naphthyl]vinyl] pyridinium betaine); FPE (N-(fluorescein-5-thiocarbamoyl)-1,2-
dihexadecanoyl-sn-glycerol-3-phosphoethanolamine); PC (egg-phosphatidylcholine); P-gp (p-
glycoprotein). 
2 
 
Abstract 
α-Tocopherol (Vitamin E) has attracted considerable attention as a potential protective or 
palliative agent. In vitro its free-radical scavenging antioxidant action has been widely 
demonstrated.  In vivo, however, vitamin E treatment exhibits negligible benefits against 
oxidative stress. α-Tocopherol influences lipid ordering within biological membranes and its 
derivatives have been suggested to inhibit the multi-drug efflux pump P-glycoprotein. This 
study employs the fluorescent membrane probe Di-8-ANEPPS to investigate whether these 
effects are connected via influences on the membrane dipole potential (MDP), an intrinsic 
property of biological membranes previously demonstrated to modulate P-glycoprotein activity.   
 
α-Tocopherol and its non free-radical scavenging succinate analogue induced similar decreases 
in the MDP of phosphatidylcholine vesicles. α-Tocopherol succinate also reduced the MDP of 
T-lymphocytes subsequently decreasing the binding affinity of Saquinavir for P-glycoprotein. 
Additionally, α-tocopherol succinate demonstrated a preference for cholesterol treated 
(membrane microdomain enriched) cells over membrane cholesterol-depleted cells. 
Microdomain disruption via cholesterol depletion decreased Saquinavir affinity for P-
glycoprotein, potentially implicating these structures in the influence of α-tocopherol succinate 
on P-glycoprotein. This study provides evidence of a microdomain dipole potential-dependent 
mechanism by which α-tocopherol analogues influence P-glycoprotein activity. These findings 
have implications for the use of α-tocopherol derivatives for drug delivery across biological 
barriers. 
 
Keywords: Antioxidants, Cholesterol, Lipid rafts, Membranes, Membrane dipole potential, P-
glycoprotein, Saquinavir, α-Tocopherol, Vitamin E 
3 
 
Introduction 
The plasma membrane of mammalian cells has diverse functions, many of which are impaired 
by oxidative damage to its constituent lipids and proteins. The effects of such damage are seen 
in conditions ranging from natural ageing to type II diabetes as well as specific diseases of the 
nervous and cardiovascular systems [1-4]. It is not surprising therefore,  that antioxidants such 
as vitamin E have attracted considerable attention as potential protective or palliative agents. In 
vitro, vitamin E has been widely demonstrated as having a free-radical scavenging antioxidant 
action [5]. However, its mechanism of action in vivo remains controversial [6, 7] as treatment 
with vitamin E has yielded negligible benefit against oxidative stress and in some instances has 
resulted in cytotoxic effects [8-11]. In the present report we demonstrate that vitamin E has the 
capability to modify the membrane dipole potential. We also show evidence that tocopherol-
dependent changes of the membrane dipole potential can lead to changes of the ligand binding 
capability of the multi-drug efflux pump P-glycoprotein (P-gp). Such observations suggest 
therefore, that it is worth considering that some of the reported effects of tocopherols may arise 
through such mechanisms [as outlined in [12]] rather than resulting solely from anti-oxidant 
properties. 
 
α-Tocopherol is the form of vitamin E most preferentially absorbed by the human body [13] 
despite the β-, γ- and δ- isoforms, and the tocotrienol counterparts, also exhibiting free radical 
scavenging action in vitro [14]. This observation, along with other evidence, supports the 
argument that α-tocopherol must have significant non-antioxidant roles not shared by other 
antioxidants [6] prompting investigations to identify the non-antioxidant physiological effects 
of α-tocopherol. α-Tocopherol succinate has received attention as an analogue of α-tocopherol 
that demonstrates no in vitro free-radical scavenging action [15] but is reported to possess 
clinically relevant effects, such as improving the efficacy of chemotherapy when administered 
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as a co-therapeutic agent [16, 17]. This effect is likely to involve the multi-drug efflux pump P-
gp, but the underlying mechanism responsible is not well understood. 
 
Both α-tocopherol and its succinate ester analogue, the structures of which are shown in Fig. 1, 
are reported to have a number of effects on model biological membranes. These include 
imparting a negative curvature stress [18] and modifying the phase behaviour of lipids; 
decreasing the enthalpy of the gel to liquid crystalline transition by influencing lipid 
organisation [19, 20] and inducing phase separation as a result of preferential association with 
specific lipids [21, 22]. The present study investigates the effect of α-tocopherol and α-
tocopherol succinate on the membrane dipole potential, which is both a sensitive indicator of 
changes in lipid organisation and that of surrounding water molecules [12, 23-28], and directly 
influences the behaviour of membrane proteins [25, 29, 30].  
 
We utilise fluorescent probes developed in our laboratories as sensitive indicators of molecular 
interactions with membranes [30]. The first, Fluorescein-phosphatidylethanolamine (FPE) is an 
indicator of the electrostatic surface potential and so reports the addition or loss of electrical 
charge to the membrane surface. The second membrane localised fluorescent probe, Di-8-
ANEPPS, reports the level of the membrane dipole potential and its use as an indicator of 
molecular interactions is described in refs [12, 25, 29, 30]. The virtue of both these indicators is 
that they can be used in exactly the same fashion in model membrane systems as in living cell 
membranes [e.g. [29]]. We use these techniques to show that in intact cells both α-tocopherol 
succinate and oxidised cholesterol, 7-ketocholesterol, decrease the dipole potential and 
influence the interaction of the Saquinavir with P-glycoprotein. 
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Materials and Methods 
Reagents 
D-α-tocopherol, D-α-tocopherol succinate, cholesterol, 7-ketocholesterol and methyl-β-
cyclodextrin were supplied by Sigma Aldrich (UK). Egg-phosphatidylcholine (PC) was 
supplied by Lipid Products (UK). Saquinavir was supplied by Roche (UK). Di-8-ANEPPS ((1-
(3-sulfonatopropyl)-4-[β[2-(di-n-octylamino)-6-naphthyl]vinyl] pyridinium betaine) and FPE 
(N-(fluorescein-5-thiocarbamoyl)-1,2-dihexadecanoyl-sn-glycerol-3-phosphoethanolamine) 
were obtained from Invitrogen (UK). Cell culture reagents including RPMI 1640, Dulbecco’s 
phosphate buffered saline (DPBS), foetal bovine serum (FBS), penicillin-streptomycin mixture, 
L-glutamine and Trypan Blue (0.4% solution) were obtained from Sigma Aldrich (UK). All 
other reagents were also supplied by Sigma Aldrich (UK) at the highest purity available. 
 
Model membrane vesicle preparation and labelling with Di-8-ANEPPS 
Large unilamellar phosphatidylcholine vesicles were prepared and labelled with Di-8-ANEPPS 
as described in ref [29]. Briefly, egg-phosphatidylcholine (PC), D-α-tocopherol, D-α-
tocopherol succinate, cholesterol and 7-ketocholesterol dissolved in 5:1 chloroform:methanol 
were combined at the desired proportions and the solvent evaporated by gentle rotation under a 
stream of oxygen-free nitrogen gas. The resulting lipid film was rehydrated with 280 mM 
sucrose, 10 mM tris, pH 7.4, and this multilamellar solution was then subject to five freeze-
thaw cycles in liquid nitrogen to promote the formation of unilamellar vesicles. Finally, the 
vesicles were extruded ten times through polycarbonate filters with 100 nm pores (Nucleopore 
Corp., Pleasanton, USA) at 45 oC using an extruder (Lipex Biomembranes Inc., Vancouver, 
Canada) according to the extrusion procedure [31]. This produced a monodisperse suspension 
of unilamellar vesicles. Vesicle compositions formed included: PC100%, PC95%X5%, PC90%X10%, 
PC85%X15%, PC80%X20%, PC75%X25% and PC70%X30% (molar ratios, X: D-α-tocopherol, D-α-
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tocopherol succinate, cholesterol or 7-ketocholesterol). Vesicles were labeled by incubation 
with 30 μM Di-8-ANEPPS dissolved in ethanol at 37 oC, protected from light, for 2 hr. 
 
Labeling of Jurkat T-Lymphocytes with Di-8-ANEPPS or FPE 
Jurkat T-Lymphocytes (E6-1 clone, ECACC) were cultured in RPMI 1640 supplemented with 
10% v/v heat inactivated FBS, 2 mM L-Glutamine, 100 U ml-1 Penicillin and 100 U ml-1 
Streptomycin and maintained at 37 oC with 5% CO2. The viable cell population was counted 
using a trypan blue exclusion assay prior to harvesting by centrifugation (300 g, 5 min). Cells 
were labelled with Di-8-ANEPPS by incubating a suspension of 1x106 cells ml-1 with 0.5 μM 
Di-8-ANEPPS for 1.5 hr at 37 oC, as outlined by [29]. Alternatively, cells were labelled with 
FPE according to the method of [32]. Briefly, the solvent was evaporated from a volume of 
FPE (2 mM in 5:1 chloroform:methanol) by gentle rotation under a stream of oxygen-free 
nitrogen gas. The resulting FPE film was resolvated in a small volume of ethanol (not 
exceeding 0.5% of the total volume of labelling solution) and diluted in 280 mM sucrose, 10 
mM tris, pH 7.4 to give a 10 μM FPE labelling solution. Cells were resuspended in this 
labelling solution at 0.5x106 cells ml-1 and incubated at 37 oC for 1 hr, protected from light. 
After this time cells were washed twice in DPBS by centrifugation (300 g, 5 min) to remove 
unbound FPE and resuspended at 0.5x106 cells ml-1 in 280 mM sucrose, 10 mM tris, pH 7.4. 
 
Depletion of cell membrane cholesterol 
Methyl-β-cyclodextrin was used to remove cholesterol from the plasma membrane of cells 
using a method adapted from [33] reported to result in the removal of most of the cholesterol 
from membrane microdomains (rafts) with negligible effects on cell viability. Following 
labelling with Di-8-ANEPPS or FPE, cells were washed twice in DPBS by centrifugation (300 
g, 5 min) before exposure to 10 mM methyl-β-cyclodextrin in 280 mM sucrose, 10 mM tris, pH 
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7.4, for 1 min. Cells were then immediately centrifuged (500 g, 2 min) and resuspended in fresh 
280 mM sucrose, 10 mM tris, pH 7.4. 
 
Cell viability 
An alamarBlue resazurin reduction assay (Invitrogen, Carlsbad, CA, USA) was used to assess 
cell viability and was performed according to the manufacturer’s instructions. After incubating 
cells with α-tocopherol succinate, cholesterol or 7-ketocholesterol at the maximum 
concentration and for the maximum exposure time relevant to this study, 10% v/v alamarBlue 
was added to the cells in a 96 well plate. After a 4 hr incubation at 37oC with 5% CO2 
fluorescent measurements were made at 590 nm with 550 nm excitation using a LS-55 plate 
reader (Perkin Elmer, MA, USA). Baseline readings were taken from culture medium and 
alamarBlue reagent without cells. 
 
Fluorescence Spectroscopy Measurements 
The spectral sensitivity of membrane bound Di-8-ANEPPS to the dipole potential was used to 
determine relative differences in the dipole potential of phospholipid vesicles of varying 
composition and the relative changes in the dipole potential on the interaction of exogenously 
introduced α-tocopherol succinate and 7-ketocholesterol with vesicles and cell membranes. Di-
8-ANEPPS excitation spectra of suspensions of vesicles (400 μM lipid) were taken between 
400 nm and 550 nm and recorded at an emission wavelength of 590 nm using a Fluoromax4 
Spectrofluorometer (Horiba Jobin Yvon, Middlesex, UK). To visualize the extent of spectral 
shift, each excitation spectrum was normalized with respect to its integral prior to subtracting 
the normalized spectrum of the reference (pure egg-phosphatidylcholine vesicles) resulting in a 
difference spectrum. A measure of the relative dipole potential of vesicles of varying 
composition was achieved by exciting the vesicle suspension at 460 nm and 520 nm and taking 
the ratio of the emission intensities recorded at 580 nm. The relative difference in the dipole 
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potential of vesicles resulting from increasing proportions of non-egg-phosphatidylcholine 
components was found by subtracting the ratio of the reference (pure egg-phosphatidylcholine 
vesicles) giving a change in the ratio. 
 
Relative changes in the membrane dipole potential on serial addition of α-tocopherol succinate, 
7-ketocholesterol or Saquinavir to vesicle or cell suspensions (400 μM lipid or 40 000 cells ml-
1) were observed, in real time, using the above ratiometric technique. The time course of the 
ratio of Di-8-ANEPPS emission intensities on rapid alternate excitation of the sample at 460 
nm and 520 nm was recorded using a Fluoromax4 Spectrofluorometer (Horiba Jobin Yvon, 
Middlesex, UK) and the relative change in the dipole potential was found by calculating the 
change in the ratio above the baseline ratio recorded at the onset of the experiment. The effect 
of any photobleaching, of dilution and of the solvent on the fluorescence signal was corrected 
by adding equivalent volumes of ethanol or dimethyl sulfoxide solvents (final concentration not 
exceeding 1% v/v) to equivalent vesicle or cell suspensions, over a comparable timeframe, and 
subtracting any resulting fluorescence ratio changes from those obtained on the addition of α-
tocopherol succinate, 7-ketocholesterol or Saquinavir. These data were fitted to both Equation 1 
& 2 and the model best describing the data was determined using an Extra sum-of-squares F-
test. 
       (1) 
      (2) 
Where y is the calculated change in the ratio, x is the cumulative concentration of α-tocopherol 
succinate, 7-ketocholesterol or Saquinavir added, Kd is the dissociation constant (concentration 
units), reflecting the affinity of the binding molecule for the membrane or receptor, Bmax is the 
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100% binding capacity of the membrane or receptor for the molecule (fluorescence units), and 
h represents the Hill coefficient i.e. as an index of cooperativity. 
 
The dissociation constants for the interaction of α-tocopherol succinate with Jurkat T-
Lymphocytes, with or without prior cholesterol treatment, were determined in a similar fashion 
by fitting Equations 1 & 2 to the recorded change in FPE fluorescence (y) with increasing 
concentration of α-tocopherol succinate (x). The time course of the fluorescence of FPE at 520 
nm with 488 nm excitation during serial addition of α-tocopherol succinate to a suspension of 
40,000 cells ml-1 was recorded. The baseline fluorescence determined at the onset of the 
experiment was subtracted giving a cumulative change in fluorescence intensity per stepwise 
increase in α-tocopherol succinate concentration representing the change in the surface 
potential. This data was likewise corrected for the effects of photobleaching, of dilution and of 
the solvent by subtracting the change in fluorescence obtained on the addition of equivalent 
volumes of solvent over a comparable time frame. Dissociation constants (Kd) and 
cooperativity (Hill) coefficients were compared using unpaired two tailed t-tests. Curve fitting 
and statistical analysis was performed using GraphPad Prism v5.04 (GraphPad Software, CA, 
USA). 
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Results 
Modulation of the membrane dipole potential by α-tocopherol and α-tocopherol succinate - The 
influence of α-tocopherol and α-tocopherol succinate on the membrane dipole potential was 
first explored in a lipid vesicle membrane system. Egg phosphatidylcholine (PC) vesicles 
containing α-tocopherol or its analogue α-tocopherol succinate were prepared using lipid film 
hydration followed by extrusion [31]. The change in the membrane dipole potential due to the 
incorporation of these forms of vitamin E was observed by the potential- dependant shift in the 
excitation spectrum of the electrochromic fluorescent probe Di-8-ANEPPS [12]. Fig. 2A (inset) 
illustrates difference spectra for tocopherol containing vesicles, obtained by subtracting the 
baseline excitation spectrum of Di-8-ANEPPS in PC vesicles from that in the α-tocopherol-
containing vesicles. α-Tocopherol induced a spectral red-shift, indicative of a decrease in 
membrane dipole potential. Also shown are the difference spectra for vesicles containing 
cholesterol and its oxidised derivative, 7-ketocholesterol, which have previously been 
demonstrated to increase and decrease the dipole potential respectively [28, 29]. The 
concentration dependence of the change in dipole potential induced by the sterols, α-tocopherol 
and α-tocopherol succinate in PC vesicles is shown in Fig. 2A. α-Tocopherol produced a 
change in the dipole potential of PC vesicles similar  in magnitude to that induced by 
cholesterol, but in the opposite direction, consistent with reports on mixed lipid membranes 
[22]. α-Tocopherol succinate, the non-free radical scavenging analogue of α-tocopherol, was 
found to have a similar effect (P= 0.09, two-tailed t-test on slopes). The influence of 7-
ketocholesterol and α-tocopherol succinate, the more soluble of the α-tocopherols, on the dipole 
potential of Jurkat T-Lymphocyte cell membranes was then explored by exposing the intact 
cells to increasing concentrations of either substance (Fig. 2B). Both decreased the dipole 
potential with 7-ketocholesterol inducing the greater effect, as was seen in PC vesicles. 
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The effect of α-tocopherol succinate on the interaction of Saquinavir with the multi-drug efflux 
pump, P-glycoprotein (P-gp) - Saquinavir, an anti-retroviral agent used in HIV therapy, is 
known to act as a ligand of the multi-drug efflux pump, P-gp [34]. These interactions can be 
observed in cell membranes as they lead to small changes of the dipole potential [29]. The 
binding of Saquinavir to Jurkat T-Lymphocytes shown in Figure 3 follows a sigmoidal profile 
indicating its interaction with a membrane localised receptor in a manner very similar to that 
found in our earlier studies with Caco-2 cells [29]. Pre-treatment of T-lymphocytes with α-
tocopherol succinate significantly reduced the affinity of Saquinavir for P-gp, demonstrated by 
an increase in the dissociation constant (Kd, see table 1) for the interaction (unpaired two-tailed 
t-test; P = 0.0012, R2= 0.945). Similarly, 7-ketocholesterol, which likewise decreases the dipole 
potential, also decreased the affinity of Saquinavir for P-gp (unpaired two-tailed t test; P = 
0.004, R2 = 0.90), consistent with reports on the influence of a change in the dipole potential on 
P-gp function [29]. Interestingly α-tocopherol succinate, which decreases the membrane dipole 
potential to a lesser extent than 7-ketocholesterol, demonstrated the larger effect on the affinity 
of Saquinavir for P-gp. The influence of 7-ketocholesterol or α-tocopherol succinate treatment 
on the shape of the binding profiles of Saquinavir may provide an explanation for the apparent 
discrepancy between the magnitude of their influence on the dipole potential and P-gp activity. 
Following 7-ketocholesterol treatment the Hill coefficient (see Table 1) of the sigmoidal 
binding profile, reflecting the extent of cooperativity in the interaction, is not significantly 
altered (unpaired two-tailed t test; P = 0.42). Following treatment with α-tocopherol succinate, 
however, the Hill coefficient is significantly reduced (unpaired two tailed t-test; P = 0.02, R2 = 
0.75). This observation suggests that α-tocopherol succinate is exerting a significant effect on 
the nature of the Saquinavir-P-gp binding mechanism that is not induced by 7-ketocholesterol. 
 
The mechanism underlying the cooperative nature of the Saquinavir-P-gp interaction is 
unknown, however, the activity of P-gp is thought to be membrane microdomain-associated 
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[35, 36]. The receptor is thought to show a preference for the elevated dipole potential 
associated with cholesterol-rich microdomains [29, 30] due to their higher lipid packing density 
and decreased hydration [28, 37]. The treatment of T-Lymphocytes with methyl-β-cyclodextrin 
to disrupt these microdomains via cholesterol depletion [33] significantly decreased the affinity 
of Saquinavir for P-gp (unpaired two-tailed t test P = 0.0002, R2 = 0.98) (Figure 3, Table 1), 
suggesting the activity of P-gp is membrane microdomain-dependant. The Hill coefficient for 
the interaction (see Table 1) was also much reduced suggesting cholesterol-rich microdomains 
may have an important role in the underlying mechanism of the Saquinavir-P-gp interaction. 
Interestingly, the effect of methyl-β-cyclodextrin and α-tocopherol succinate on the 
cooperativity of the Saquinavir-P-gp interaction are similar (unpaired two tailed t-test on Hill 
coefficients; P = 0.09). We suggest that α-tocopherol succinate influences P-gp by decreasing 
the dipole potential of P-gp that is associated with membrane microdomains. 
 
We frame this hypothesis as follows: α-Tocopherol succinate localises in cholesterol-rich 
membrane microdomains where it acts to decrease the dipole potential - To explore this 
hypothesis the interaction of α-tocopherol succinate with cells enriched with, or depleted of, 
cholesterol-rich microdomains was investigated. T-lymphocytes were treated with cholesterol 
to increase the extent of cholesterol-rich microdomains in the plasma membrane or with 
methyl-β-cyclodextrin to induce microdomain disruption. The dissociation constant for α-
tocopherol succinate binding to these treated cells, determined from binding curves formed 
from measurements of the change in surface or dipole potential induced by the binding 
interaction [30], was compared to that for α-tocopherol succinate binding to untreated cells 
(Fig.4). Cholesterol treatment significantly increased the affinity of α-tocopherol succinate for 
the membrane (unpaired two-tailed t-test on Kd values, P = 0.0058) whereas methyl-β-
cyclodextrin treatment had the opposite effect (unpaired two-tailed t-test on Kd values, P < 
0.0001). The increased affinity of α-tocopherol succinate for membranes rich in microdomains 
13 
 
suggests it has a preference towards these structures and is likely to decrease the dipole 
potential with lateral heterogeneity across the membrane. 
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Discussion 
The present study demonstrates that the interaction of α-tocopherol and its water soluble 
derivative, α-tocopherol succinate, with biological membranes leads to changes of the 
membrane dipole potential. A schematic representation of these interactions and their effects in 
relation to those of cholesterol is shown in Fig. 5. As α-tocopherol succinate is a non-free 
radical scavenging analogue of α-tocopherol, this effect is independent of, and may be 
additional to, any free radical scavenging activity for α-tocopherol.  
 
Supplementing membranes with α-tocopherol succinate appears to influence the interaction of 
the anti-retroviral agent Saquinavir most likely through effects on the multi-drug efflux pump, 
P-gp. This membrane receptor is reported to be sensitive to change in the dipole potential [29] 
and its activity is linked here and elsewhere [29, 38, 39] with cholesterol-rich membrane 
microdomains. α-Tocopherol succinate is shown to have a preferential affinity for membranes 
rich in these microdomains suggesting its possible localisation within these structures. While 
direct evidence for the association of tocopherol succinate with cholesterol enriched membrane 
microdomains remains elusive, this hypothesis is supported by previous observations that the 
membrane localisation of tocopherol succinate influences the activity of microdomain-
associated kinases, including protein kinase C [40, 41]. In the present study, the membrane 
interactions of tocopherol succinate were also shown to influence the nature of the Saquinavir-
P-gp interaction with similar effect to microdomain disruption via membrane cholesterol 
depletion. We hypothesize that the mechanism by which α-tocopherol succinate influences P-
gp is via its effect to decrease the dipole potential of membrane microdomains with which this 
receptor associates. In support of this notion, 7-ketocholesterol, an oxidised form of cholesterol 
known to localise in cholesterol-rich microdomains [42, 43] and demonstrated to decrease the 
dipole potential of the plasma membrane, was also shown to influence the interaction of 
Saquinavir with P-gp. The apparent differences in the extent to which α-tocopherol succinate 
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and 7-ketocholesterol influence both the dipole potential and P-gp are suggested to be due to 
differences in their heterogeneous lateral distribution within membranes and, in particular, their 
extent of co-localisation with P-gp in microdomains. The specific influence of molecules on the 
microdomain profile of membranes and the resulting lateral heterogeneity in dipole potential 
modulation across the membrane are likely to be factors which correlate more directly with 
microdomain-associated receptor activity. 
 
The implications of α-tocopherol succinate modulation of P-gp activity are significant. The 
cytotoxicity of many native and xenobiotic compounds could be increased due to the reduced 
ability of P-gp to remove them from the cell. In addition to the potential negative side effects 
this may cause, α-tocopherol succinate treatment may increase the efficacy of applied 
therapeutic agents by improved cellular retention. In addition, α-tocopherol succinate may also 
have a role in countering multi-drug resistance. This phenomenon is associated with P-gp 
which is able to remove a wide variety of chemically unrelated drugs from cells including 
antibiotics, anti-cancer agents and anti-HIV agents such as Saquinavir [44-46]. For example, 
increased expression of P-gp is observed in some cancerous tumour cells [47] and the 
consequent increase in drug resistance is associated with the failure of chemotherapy [45, 46]. 
Interestingly, α-tocopherol succinate treatment has been shown to increase the efficacy of some 
chemotherapeutic agents [16, 17] and this effect could be explained therefore, by a similar 
mechanism to that proposed in our present work. 
 
Drug delivery across biological barriers is presently considered a major bottle-neck for 
the delivery of therapeutics to target tissues [48]. Multidrug resistance (MDR) 
transporters such as P-gp (MDR1) play an important role in maintaining epithelial and 
endothelial  barrier function by actively transporting a wide variety of predominantly 
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small hydrophobic xenobiotics and toxins out of cells [49]. P-gp is expressed in 
multiple biological barriers including the blood-brain [50], blood-retinal [51], corneal 
[52] and intestinal mucosal barriers [53]. In addition, over expression of this protein has 
also long been known to play a central role in the development of multi-drug resistant 
cancer [54]. Inhibitors of P-gp, are well documented to improve drug delivery across 
biological barriers [55, 56], enhance bioavailability of orally administered therapeutics 
[57] and overcome multi-drug resistant cancers [58]. For these reason there has been 
considerable interest in the development of well tolerated P-gp inhibitors [49]. For 
example, α-tocopherol polyethylene glycol succinate is reported to enhance oral absorption of 
several therapeutic compounds, including Cyclosporin, Paclitaxel, Doxorubicin, Vinblastine 
and Colchicine, through P-gp inhibition [44, 59]. This PEGylated α-tocopherol succinate is 
likely to influence the dipole potential in a similar manner to α-tocopherol and its non-
PEGylated succinate ester and modulate P-gp activity via the same mechanism. 
 
The dipole potential is a determinant of the functions of various membrane proteins in addition 
to the P-gp investigated in the present study, and many proteins have been identified as being 
present in membrane microdomains. Our observations may therefore apply to a variety of 
proteins and different cell types. α-Tocopherol, through its localisation in membrane 
microdomains [43], may influence the function of microdomain-associated proteins via the 
same mechanism we propose for α-tocopherol succinate. Indeed the ubiquity of this mechanism 
may help to explain the diverse and, sometimes apparently contradictory, actions which have 
been ascribed to vitamin E.  
 
In conclusion, the present study demonstrates that α-tocopherol and α-tocopherol succinate 
modulate the dipole potential of artificial and cell membranes. This effect may contribute 
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towards an explanation of the diverse physiological actions of Vitamin E. In addition, this 
effect forms the basis of a mechanism for the indirect inhibition of P-gp by α-tocopherol 
derivatives, highlighting the potential for the application of these compounds in countering 
multi-drug resistance and in facilitating drug delivery across biological barriers.  
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Figure Legends 
Figure 1: Planar schematic and space-filling model views of [A] α-Tocopherol and [B] α-
Tocopherol succinate. Images were prepared using ACD/ChemSketch (freeware), version 
C10E41 (2015) and ACD/3D Viewer (Freeware), version D10E41 (2014), Advanced 
Chemistry Development, Inc., Toronto, ON, Canada, www.acdlabs.com 
 
Figure 2: The relative dipole potential modulation of cell and vesicle membranes by α-
tocopherols and sterols. [A] (inset) Difference spectra demonstrating the blue or red shift of 
the excitation spectrum of Di-8-ANEPPS in pure egg-phosphatidylcholine (PC) 100 nm 
vesicles in response to a relative increase or decrease of the dipole potential, respectively. 
Inclusion of 10 mol% cholesterol (blue line) in PC vesicles increased the dipole potential 
whereas 10 mol% α-tocopherol (black line) or 7-ketocholesterol (red line) decreased the dipole 
potential. [A] (main) The change in ratio of Di-8-ANEPPS fluorescence intensity at 460 nm 
and 520 nm excitation (R = I460/I520) with increasing concentration of α-tocopherol (diamonds), 
α-tocopherol succinate (upward triangles), cholesterol (circles) or 7-ketocholesterol (squares). 
An increasing ratio reflects a blue-shifting of the excitation spectrum indicating an increasing 
dipole potential and vice versa.  [B] The decrease in membrane dipole potential of T-
lymphocyte cells on exposure to increasing concentrations of α-tocopherol succinate (solid line) 
or 7-ketocholesterol (dashed line). Values represented are mean ± SE for three replicate 
experiments. 
 
Figure 3: The interaction of Saquinavir with T-Lymphocytes following α-tocopherol 
succinate, 7-ketocholesterol or methyl-β-cyclodextrin treatment. The binding of Saquinavir 
to T-Lymphocytes is observed through the change in ratio of Di-8-ANEPPS fluorescence 
intensity at 460 nm and 520 nm excitation (R = I460/I520) reflecting the change in the cell 
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membrane dipole potential induced by the interaction. The binding curve for Saquinavir to 
untreated cells (black, solid line) and cells treated with methyl-β-cyclodextrin (black, dashed 
line) to disrupt cholesterol-rich membrane microdomains are shown in addition to the binding 
curves to cells pre-treated with α-tocopherol succinate (blue) or 7-ketocholesterol (red). Values 
represented are mean ± SE for three replicate experiments. 
 
Figure 4: The influence of cholesterol-rich cell membrane microdomains on the binding 
affinity of α-tocopherol succinate. The dissociation constants for the interaction of α-
tocopherol succinate with T-lymphocytes pre-treated with cholesterol (increasing the extent of 
membrane microdomains) or methyl-β-cyclodextrin (reducing the extent of membrane 
microdomains) are compared to those for untreated cells. Treatment with cholesterol (chol) 
significantly increased the affinity of α-tocopherol succinate for the membrane whereas 
treatment with methyl-β-cyclodextrin (MβCD) had the opposite effect. The binding interaction 
was observed through the modulation of the membrane surface potential detected using the 
fluorescent probe FPE for the cholesterol treatment experiment and through the modulation of 
the membrane dipole potential for the methyl-β-cyclodextrin treatment experiment. Values 
represented are mean ± SE for three replicate experiments. 
 
Figure 5: Schematic comparison of the interaction of cholesterol and α-tocopherol with 
biological membranes. [A] Cholesterol is well documented to form microdomains of 
increased packing density and elevated dipole potential in phospholipid membranes. [B] In this 
study we report that addition of α-tocopherol to egg phosphatidylcholine membranes causes a 
reduction in the dipole potential. A possible explanation for this phenomenon is that α-
tocopherol sits higher in the membrane, closer to the aqueous interface, than cholesterol thereby 
increasing phospholipid lipid headgroup spacing. [C] In this model the insertion of α-
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tocopherol into cholesterol-rich microdomains would reduce the lipid packing density and 
membrane dipole potential.  [D] The observation that α-tocopherol succinate modulates the 
dipole potential to a similar extent to α-tocopherol suggests that both forms interact similarly 
with membranes and supports the hypothesis that they sit high in the membrane such that the 
addition of the succinate group does not additionally perturb the dipole potential. 
 
Table 1: The dissociation constants and Hill coefficients for the interaction of Saquinavir 
with pre-treated T-Lymphocytes.  The dissociation constants (Kd) and Hill coefficients 
(±SEM) obtained from best fits of a Sigmoidal binding model to the data presented in Figure 3 
for the interaction of Saquinavir with T-lymphocytes, either untreated or pre-treated with 7-
ketocholesterol (7-KC), α-tocopherol succinate (α-TS) or methyl-β-cyclodextrin (MβCD). 
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Table 1 
 
Treatment Kd (μM) Hill coefficient 
untreated 36±1 7±1 
7-KC 47±1 9±2 
α-TS 52±2 3.4±0.2 
MβCD 68±2 4.4±0.4 
 
 
 
